ZY THERAPEUTICS INC.
Small molecule therapeutics targeting intracranial calcifications (brain stones) in rare diseases
- Sector
- Biotech
- Headquarters
- CARY, NC
- Founded
- 2015
- Latest Form D
- $6M, Jun 2016
- Total capital
- $6M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $6M
- 1 Form D · last Jun 2016
- 124 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 5 pending · first 2019
- Rank in peer group#397 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$6M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#397 · top 27%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- JUN LIResearcherExecutive Officer, DirectorLinked by 2 patents
- JIAN BAOExecutive Officer, DirectorNamed in SEC Form D filings
- NAN LIDirectorNamed in SEC Form D filings
- YONGMING ZHANGDirectorNamed in SEC Form D filings
- ZIYI WANGDirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 7- GrantedDrug Formulation Based On Particulates Comprising Polysaccharide-vitamin ConjugateUSPTOUS 10,994,024
- PendingPharmaceutical Composition For In Vivo Delivery, Method Of Preparation Of A Substantially Water-insoluble Pharmacologically Active Agent For In Vivo Delivery, And Method Of Treating DiseaseUSPTOApplication 16659171
- GrantedDrug Formulation Based On Particulates Comprising Polysaccharide-vitamin ConjugateUSPTOUS 10,517,961
Show all 7 patent records
- Drug Formulation Based On Particulates Comprising Polysaccharide-vitamin ConjugateMay 4, 2021 · US 10,994,024Granted
- Pharmaceutical Composition For In Vivo Delivery, Method Of Preparation Of A Substantially Water-insoluble Pharmacologically Active Agent For In Vivo Delivery, And Method Of Treating DiseaseFeb 20, 2020 · Application 16659171Pending
- Drug Formulation Based On Particulates Comprising Polysaccharide-vitamin ConjugateDec 31, 2019 · US 10,517,961Granted
- Pharmaceutical Composition For In Vivo Delivery, Method Of Preparation Of A Substantially Water-insoluble Pharmacologically Active Agent For In Vivo Delivery, And Method Of Treating DiseaseApplication PCTUS2018028900Pending
- Pharmaceutical Composition For In Vivo Delivery, Method Of Preparation Of A Substantially Water-insoluble Pharmacologically Active Agent For In Vivo Delivery, And Method Of Treating DiseaseApplication 62489198Pending
- Drug Formulation Based On Particulates Comprising Polysaccharide-vitamin ConjugateApplication PCTUS2016053626Pending
- Drug Formulation Based On Polysaccharide-vitamin ConjugateApplication 62233112Pending
Related companies, and why
- Neo Quantum Era Inc.Similar federal contract value in Biotech · null in contracts
- NRX Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- Stratos Genomics Inc.Similar federal contract value in Biotech · null in contracts
- Reprogram Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
- Cynaptec Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- Replicate Bioscience, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .